Dapagliflozin Cardiovascular and Renal Protection

Introduction to Dapagliflozin Benefits

The European Society of Cardiology recommends dapagliflozin in patients with type 2 diabetes and established cardiovascular disease or very high/high cardiovascular risk to reduce cardiovascular events, independent of glycemic control needs 3
The American Diabetes Association also recommends dapagliflozin for patients with type 2 diabetes and established cardiovascular disease or very high/high cardiovascular risk to reduce cardiovascular events 4

Dapagliflozin reduced the primary composite renal endpoint by 39% in patients with chronic kidney disease and albuminuria, regardless of diabetes status 1
The kidney-specific composite was reduced by 44% in patients with chronic kidney disease and albuminuria treated with dapagliflozin 2

Dapagliflozin is recommended at a fixed dose of 10 mg once daily for cardiovascular and renal protection, regardless of eGFR level, as long as ≥25 mL/min/1.73 m² 1

Genital mycotic infections occurred in approximately 6% of patients treated with dapagliflozin versus 1% on placebo 1
Dapagliflozin should be withheld at least 3 days before major surgery or procedures requiring prolonged fasting to prevent postoperative ketoacidosis 1
Volume depletion risk is higher in elderly patients and those on concurrent diuretics, requiring assessment before initiation of dapagliflozin 1
An initial reversible eGFR dip of 3-5 mL/min/1.73 m² typically occurs within 1-4 weeks, followed by long-term renal protection with dapagliflozin 1